Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

EMERGE is initiating a global randomized Phase 3 trial for claseprubart 300mg/2mL subcutaneous dosing every 2 weeks (Q2W) and 4 weeks (Q4W) versus placebo, with top-line results expected in 2H’28. The update is primarily development-stage and provides no near-term efficacy or safety readout yet.

Analysis

EMERGE is initiating a global randomized Phase 3 trial for claseprubart 300mg/2mL subcutaneous dosing every 2 weeks (Q2W) and 4 weeks (Q4W) versus placebo, with top-line results expected in 2H’28. The update is primarily development-stage and provides no near-term efficacy or safety readout yet.